Yoland Antill

3.2k total citations
11 papers, 166 citations indexed

About

Yoland Antill is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Yoland Antill has authored 11 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 3 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Yoland Antill's work include BRCA gene mutations in cancer (5 papers), Endometrial and Cervical Cancer Treatments (2 papers) and Cancer Genomics and Diagnostics (2 papers). Yoland Antill is often cited by papers focused on BRCA gene mutations in cancer (5 papers), Endometrial and Cervical Cancer Treatments (2 papers) and Cancer Genomics and Diagnostics (2 papers). Yoland Antill collaborates with scholars based in Australia, Japan and South Korea. Yoland Antill's co-authors include Sumitra Ananda, C. David Wrede, Anne Hamilton, Geoffrey J. Lindeman, Clare L. Scott, Maira Kentwell, Orla McNally, Emily Higgs, Mary‐Anne Young and John Reynolds and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and Annals of Oncology.

In The Last Decade

Yoland Antill

8 papers receiving 163 citations

Peers

Countries citing papers authored by Yoland Antill

Since Specialization

Citations

This map shows the geographic impact of Yoland Antill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoland Antill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoland Antill more than expected).

Fields of papers citing papers by Yoland Antill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoland Antill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoland Antill. The network helps show where Yoland Antill may publish in the future.

Co-authorship network of co-authors of Yoland Antill

This figure shows the co-authorship network connecting the top 25 collaborators of Yoland Antill. A scholar is included among the top collaborators of Yoland Antill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoland Antill. Yoland Antill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	LBA39 Final overall survival (OS) results from the randomized double-blind phase III AtTEnd/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer 2025 ·Annals of Oncology ·M.P. Barretina Ginesta, Elena Biagioli, Kenichi Harano, Francesca Galli, (unknown), Yoland Antill, (unknown), Manuela Rabaglio, (unknown), Elisa Piovano, Katharina Leitner, (unknown), Kazuhiro Takehara, (unknown), (unknown), Claudio Zamagni, (unknown), Giulia Tasca, Annamaria Ferrero, (unknown)	0
2	713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial 2024 ·Annals of Oncology ·Oliver Klein, Matteo S. Carlino, (unknown), Craig Underhill, Jimmy Bok Yan So, Damien Kee, Yoland Antill, (unknown), Henry Chan, Rosemary Harrup, (unknown), Jamie Palmer, Dawn Thomas, (unknown), Jonathan Cebon, Bo Gao	5
3	793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005 2024 ·Annals of Oncology ·(unknown), Mansoor Raza Mirza, J. Martin-Babau, Alessandra Bologna, M.P. Barretina Ginesta, (unknown), Jason A. Wampfler, David Cibula, Jianqing Zhu, (unknown), (unknown), June‐Yong Lee, (unknown), Yoland Antill, Michelle Lightfoot, (unknown), (unknown), Ying Cui, (unknown), (unknown)	2
4	16P Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment 2023 ·Annals of Oncology ·(unknown), Yoland Antill, (unknown), Carlos Shimizu, (unknown), L-M Tseng, (unknown), (unknown), (unknown), (unknown), David S. Hsu	0
5	Enhanced Toxicity With Trastuzumab Emtansine And Concurrent Adjuvant Radiotherapy: Non-Consecutive Case Series 2023 ·The Breast ·(unknown), Keelan Byrne, Michelle J. White, Yoland Antill, Karen J. Taylor, Jennifer Pei-Ling Tan, (unknown), Steven David	0
6	Uptake of polygenic risk information among women at increased risk of breast cancer 2019 ·Clinical Genetics ·Tatiane Yanes, Bettina Meiser, Rajneesh Kaur, (unknown), Simone McInerny, (unknown), Kristine Barlow‐Stewart, Yoland Antill, Lucinda Salmon, (unknown), Mary‐Anne Young, Paul A. James	19
7	Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer 2019 ·JNCI Journal of the National Cancer Institute ·Na Li, Simone McInerny, Magnus Zethoven, Dane Cheasley, (unknown), Simone M. Rowley, Lisa Devereux, (unknown), (unknown), David J. Byrne, (unknown), Jason Li, Stephen B. Fox, Thomas John, Yoland Antill, Kylie L. Gorringe, Paul A. James, Ian Campbell	23
8	Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics 2017 ·Gynecologic Oncology ·Maira Kentwell, (unknown), Yoland Antill, C. David Wrede, Orla McNally, Emily Higgs, Anne Hamilton, Sumitra Ananda, Geoffrey J. Lindeman, Clare L. Scott	80
9	Abstract P5-15-02: Indications for, and impact of oncotype DX on adjuvant treatment recommendations when third party funding is unavailable 2016 ·Cancer Research ·(unknown), Eva Segelov, R. de Boer, Gavin Marx, (unknown), Nicole McCarthy, Shane White, S. Foo, J Rutovitz, (unknown), Ross Jennens, Yoland Antill, (unknown), (unknown), Janine Lombard, (unknown), (unknown), Alexandra Gorelik, G. Bruce Mann	1
10	Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer 2010 ·ANZ Journal of Surgery ·Belinda E. Kiely, (unknown), (unknown), (unknown), (unknown), Kate Moodie, Yoland Antill, Gillian Mitchell	2
11	Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer 2006 ·European Journal of Cancer ·Yoland Antill, John Reynolds, Mary‐Anne Young, Judy Kirk, Kathy Tucker, (unknown), Shirley Wong, Tracy Dudding, Juliana Di Iulio, Kelly‐Anne Phillips	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact